No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
There's No Escaping LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Muted Revenues Despite A 26% Share Price Rise
Lakeside Biological released its unaudited financial performance for the first half of the 2025 fiscal year and updated the financial guidance for the entire year.
In the first half of the 2025 fiscal year, revenue reached 0.3719 billion yuan, a year-on-year increase of 36.2%. The gross profit for the first half of the 2025 fiscal year was 0.3073 billion yuan, an increase of 39.1% year-on-year; the gross margin increased from 80.9% in the same period last year to 82.6%. Total operating expenses in the first half of the 2025 fiscal year decreased by 31.6%, totaling 0.2764 billion yuan. The net income for the first half of the 2025 fiscal year was 20.58 million yuan, while the net income under non-GAAP was 30.45 million yuan; in the same period of 2024, the recorded figures were (under GAAP and non-GAAP.
LakeShore Biopharma Sees FY25 Revenues To Be Between RMB 665 Million - RMB 700 Million, Indicating Growth Of 16%-22% YoY
Express News | LakeShore Biopharma H1 2025 EPS $0.02; Revenue $53.08M
Press Release: LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
